Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial

Keywords: Helicobacter Pylori, Vonoprazan, Proton Pump Inhibitors, Clarithromycin, Amoxiciline

Abstract

Objectives: To compare the efficacy of Vonoprazan based dual treatment versus PPI based treatment for the eradication of Helicobacter pylori infection.

Methods: A randomized controlled trial was conducted in Department of Medicine/Gastroenterology Ruth KM Pfau Civil Hospital, DMC during the period of 22 June to 21 September 2021. Sample size was calculated as 96 in each Group. All patients of age 18-75 years with Helicobacter Pylori Infection were inducted and randomly allocated to two groups. Group-A: were given Capsule Amoxicillin 1 gm; Tablet Clarithromycin 500 mg; Capsule Omeprazole 20 mg all medications were given twice daily for two weeks. Group-B were given Capsule Amoxicillin 1 gm; Tablet Vonoprazan 20 mg (Vonozon©, m/s Getz Pharma, Pakistan) twice daily for two weeks. Confirmation of Hp eradication was done by stool Hp antigen test four weeks after completion of treatment. Nine and four patients were lost to follow-up in Group-A & B respectively. Analysis was conducted on 87 patients in Group-A and 92 patients in Group-B.

Results: Out of eighty-seven patients in Group-A and ninety-two patients in Group-B, 73 (83.9%) patients in Group-A and 86 (93.5%) patients in Group-B had negative H pylori result respectively after treatment (p = .042). Significantly higher frequencies of adverse events were observed in Group-A as compared to Group-B in nausea/vomiting (p = .035) and bloating (p = .045).

Conclusion: VA-dual provides an acceptable eradication rate with fewer adverse events.

doi: https://doi.org/10.12669/pjms.38.4.5436

How to cite this:
Zuberi BF, Ali FS, Rasheed T, Bader N, Hussain SM, Saleem A. Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial . Pak J Med Sci. 2022;38(4):965-969. doi: https://doi.org/10.12669/pjms.38.4.5436

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Biographies

Bader Faiyaz Zuberi, Dow University of Health Sciences

Gastroenterologist and Hepatologist
Professor of Medicine
Chairman Department of Medicine
Director Institute of Clinical Sciences
Director Clinical Trials Unit
Dow Medical College
Karachi, Pakistan

Faiza Sadaqat Ali, Dow University of Health Sciences, Karachi, Pakistan

Senior Registrar

Tazeen Rasheed, Dow University of Health Sciences, Karachi, Pakistan

Assistant Professor

Nimrah Bader, University of Miami/Jackson Health System, Miami, FL

PG&-4 Fellow in Geriatrics

 

Sana Muhammad Hussain, Dow University of Health Sciences, Karachi, Pakistan

PG Trainee

Anoshia Saleem, Dr Ruth KM Pfau Civil Hospital Karachi

Consultant

Published
2022-03-07
How to Cite
Zuberi, B. F., Ali, F. S., Rasheed, T., Bader, N., Hussain, S. M., & Saleem, A. (2022). Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial. Pakistan Journal of Medical Sciences, 38(4). https://doi.org/10.12669/pjms.38.4.5436

Most read articles by the same author(s)

<< < 1 2